OncoMatch/Clinical Trials/NCT05733715
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Is NCT05733715 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Pembrolizumab infusion and Lenvatinib tablet for renal cell carcinoma.
Treatment: Pembrolizumab infusion · Lenvatinib tablet — This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent
Cannot have received: co-inhibitory T-cell receptor therapy
agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)
Cannot have received: systemic anti-cancer therapy
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to randomization
Lab requirements
Kidney function
Subjects having > 1+ proteinuria on urine dipstick testing, unless a 25-hour urine collection for quantitative assessment indicates that the urine protein is <1 g/24 hours.
Liver function
Have adequate organ function
Cardiac function
Has a LVEF ≤40%, as determined by multigated acquisition (MUGA) or echocardiogram (ECHO). Prolongation of QTcF interval to >480 ms.
Have adequate organ function. Has a LVEF ≤40%, as determined by multigated acquisition (MUGA) or echocardiogram (ECHO). Prolongation of QTcF interval to >480 ms. Subjects having > 1+ proteinuria on urine dipstick testing, unless a 25-hour urine collection for quantitative assessment indicates that the urine protein is <1 g/24 hours.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Abramson Cancer Center at University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify